+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Tuberculosis Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sale

Tuberculosis Drugs Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 194 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 4985928
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Drugs Market grew from USD 2.04 billion in 2024 to USD 2.18 billion in 2025. It is expected to continue growing at a CAGR of 6.30%, reaching USD 2.95 billion by 2030.

Tuberculosis remains one of the leading infectious diseases worldwide, challenging health systems, policymakers, and pharmaceutical innovators alike. Despite advances in diagnostics and treatment, gaps persist in drug efficacy, adherence, and access-especially where multidrug-resistant strains arise. Recent scientific breakthroughs and shifting regulatory priorities have converged to reshape both the development pipeline and the supply chain for anti-TB therapies. As public and private stakeholders respond to evolving patient needs, a comprehensive view of market dynamics is essential. This executive summary synthesizes the most critical developments-from novel therapeutic candidates to tariff-driven cost pressures-and equips decision-makers with insights to navigate complexity, optimize investments, and accelerate patient impact.

Transformative Shifts Redefining the Tuberculosis Treatment Paradigm

The past several years have witnessed transformative shifts across the tuberculosis drug landscape. First, the rise of fixed-dose combinations and customized regimens has simplified dosing and improved adherence. Simultaneously, novel therapeutic agents such as bedaquiline and delamanid have emerged to address resistant strains, forging a new class of targeted treatments. Policy environments have also evolved: expedited regulatory pathways and patent-linkage mechanisms have shortened time-to-market, while public-private partnerships have fueled collaborative R&D. Furthermore, digital health platforms are integrating treatment monitoring and patient support, enabling real-time adherence tracking. As a result, stakeholders must adapt to a more dynamic ecosystem where scientific innovation, regulatory agility, and patient engagement converge to redefine standard of care.

Assessing the Cumulative Impact of United States Tariffs in 2025 on TB Drug Supply

In 2025, new United States tariffs on imported active pharmaceutical ingredients and finished formulations have reshaped cost structures and supply reliability. Manufacturers reliant on global raw material sourcing have encountered higher input costs, prompting near-term price adjustments and renegotiation of supplier agreements. Some producers have accelerated vertical integration or relocated key manufacturing steps to tariff-free jurisdictions to mitigate exposure. These shifts have also influenced negotiating leverage between drug developers and national health systems, with cost containment measures gaining urgency. At the same time, R&D pipelines have been reprioritized to focus on formulations less susceptible to tariff fluctuations, for example, novel oral therapies with lower manufacturing complexity. Ultimately, this tariff regime has underscored the importance of diversified supply chains and proactive policy engagement to sustain patient access.

Key Segmentation Insights Uncovering Diverse Patient and Product Needs

A nuanced understanding of patient and product segments is critical for targeted strategy. When examining product type, combination drugs span both customized combination therapies and fixed-dose combinations; first-line anti-TB agents include ethambutol, isoniazid, pyrazinamide and rifampicin; novel therapeutics feature bedaquiline and delamanid; and second-line drugs cover fluoroquinolones such as levofloxacin and moxifloxacin plus injectable options amikacin and capreomycin. Therapy duration divides into long-course and short-course approaches, each demanding distinct adherence support. Drug origin is split between natural and herbal compounds versus synthetic entities, affecting regulatory and manufacturing pathways. Distribution channels range from hospital pharmacies to online pharmacies and retail outlets, shaping patient convenience and margin structures. End-user settings include homecare, hospitals and specialty clinics, highlighting varied training and logistical needs. Finally, latent tuberculosis encompasses a unique disease category requiring preventative regimens. Insights drawn from these dimensions reveal that integrating fixed-dose combinations into short-course therapy boosts adherence, while tiered distribution strategies improve reach across both urban hospital systems and remote homecare programs.

Key Regional Insights Highlighting Global Market Dynamics

Regional demand contours vary significantly. In the Americas, established reimbursement frameworks and advanced healthcare infrastructure enable rapid adoption of novel therapeutic profiles, though payer scrutiny on cost-effectiveness remains rigorous. In Europe, Middle East & Africa, heterogeneous healthcare systems present both challenges and opportunities: high-burden areas in parts of Africa and the Middle East require affordable generics, whereas Western Europe prioritizes next-generation drugs approved via accelerated pathways. The Asia-Pacific region, bearing the highest tuberculosis burden globally, leverages large-scale public screening programs and strong generics manufacturing capacity. Governments across this region are incentivizing innovative combination therapies to shorten treatment duration and minimize resistance, while online pharmacies are emerging as critical channels for expanding rural access.

Key Company Insights Shaping Competitive Strategies

Major companies are crafting differentiated strategies to secure market share. AbbVie Inc. is strengthening its pipeline through strategic licensing of fixed-dose combinations. AstraZeneca PLC is exploring partnerships to advance novel bedaquiline analogues. Bayer AG continues to invest in first-line agent optimization and pediatric formulations. Bristol Myers Squibb Company leverages its oncology expertise to fast-track anti-TB candidates with novel mechanisms. Cipla Limited and Lupin Limited, as generics leaders, are expanding capacity to meet affordability mandates in high-burden markets. Eli Lilly and Company and Merck & Co., Inc. are prioritizing R&D into short-course regimens and drug resistance biomarkers. F. Hoffmann-La Roche AG integrates diagnostics with therapeutic platforms. Johnson & Johnson Services, Inc. is scaling up manufacturing of injectable formulations. Novartis AG and Otsuka Pharmaceutical Co., Ltd. focus on global access programs. Pfizer, Inc., Sanofi S.A. and Takeda Pharmaceutical Company are refining global distribution networks to navigate tariff-impacted supply chains.

Actionable Recommendations for Industry Leaders Navigating the TB Drug Market

Industry leaders should adopt a multipronged approach. First, align R&D investment with high-value segments such as short-course fixed-dose combinations and novel resistance-targeting therapeutics. Second, establish strategic alliances across public and private sectors to share risk and accelerate clinical development. Third, diversify supply chains by qualifying multiple API suppliers and exploring regional manufacturing hubs. Fourth, enhance patient adherence through integrated digital health solutions and community-based support. Fifth, design tiered pricing and access models to balance affordability in high-burden countries with sustainable margins in developed markets. Finally, engage proactively with policymakers to influence tariff policies and regulatory reforms, ensuring long-term resilience and patient impact.

Conclusion: Charting a Strategic Path Forward

In a landscape marked by scientific breakthroughs and policy shifts, success hinges on agility, collaboration and patient-centric innovation. By leveraging segmentation data to tailor product portfolios, adapting to tariff-driven cost structures and forging strategic partnerships, stakeholders can overcome barriers to access and drive meaningful outcomes. Embracing digital tools for adherence monitoring and real-world evidence generation will further differentiate offerings and support payer negotiations. Ultimately, integrating these strategies into a cohesive roadmap will position companies to accelerate progress against tuberculosis, benefiting both global health and business performance.

Market Segmentation & Coverage

This research report categorizes the Tuberculosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Combination Drugs
    • Customized Combination Therapies
    • Fixed-Dose Combinations
  • First-Line Anti-TB Drugs
    • Ethambutol
    • Isoniazid
    • Pyrazinamide
    • Rifampicin
  • Novel Therapeutics
    • Bedaquiline
    • Delamanid
  • Second-Line Anti-TB Drugs
    • Fluoroquinolones
      • Levofloxacin
      • Moxifloxacin
    • Injectable Anti-TB Drugs
      • Amikacin
      • Capreomycin
  • Long-Course Therapy
  • Short-Course Therapy
  • Natural and Herbal Drugs
  • Synthetic Drugs
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Homecare Settings
  • Hospitals
  • Specialty Clinics
  • Latent Tuberculosis

This research report categorizes the Tuberculosis Drugs Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tuberculosis Drugs Market to delves into recent significant developments and analyze trends in each of the following companies:

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tuberculosis Drugs Market, by Product Type
8.1. Introduction
8.2. Combination Drugs
8.2.1. Customized Combination Therapies
8.2.2. Fixed-Dose Combinations
8.3. First-Line Anti-TB Drugs
8.3.1. Ethambutol
8.3.2. Isoniazid
8.3.3. Pyrazinamide
8.3.4. Rifampicin
8.4. Novel Therapeutics
8.4.1. Bedaquiline
8.4.2. Delamanid
8.5. Second-Line Anti-TB Drugs
8.5.1. Fluoroquinolones
8.5.1.1. Levofloxacin
8.5.1.2. Moxifloxacin
8.5.2. Injectable Anti-TB Drugs
8.5.2.1. Amikacin
8.5.2.2. Capreomycin
9. Tuberculosis Drugs Market, by Therapy Type
9.1. Introduction
9.2. Long-Course Therapy
9.3. Short-Course Therapy
10. Tuberculosis Drugs Market, by Drug Origin
10.1. Introduction
10.2. Natural and Herbal Drugs
10.3. Synthetic Drugs
11. Tuberculosis Drugs Market, by Distribution Channel
11.1. Introduction
11.2. Hospital Pharmacies
11.3. Online Pharmacies
11.4. Retail Pharmacies
12. Tuberculosis Drugs Market, by End-User
12.1. Introduction
12.2. Homecare Settings
12.3. Hospitals
12.4. Specialty Clinics
13. Tuberculosis Drugs Market, by Disease Type
13.1. Introduction
13.2. Latent Tuberculosis
14. Americas Tuberculosis Drugs Market
14.1. Introduction
14.2. Argentina
14.3. Brazil
14.4. Canada
14.5. Mexico
14.6. United States
15. Asia-Pacific Tuberculosis Drugs Market
15.1. Introduction
15.2. Australia
15.3. China
15.4. India
15.5. Indonesia
15.6. Japan
15.7. Malaysia
15.8. Philippines
15.9. Singapore
15.10. South Korea
15.11. Taiwan
15.12. Thailand
15.13. Vietnam
16. Europe, Middle East & Africa Tuberculosis Drugs Market
16.1. Introduction
16.2. Denmark
16.3. Egypt
16.4. Finland
16.5. France
16.6. Germany
16.7. Israel
16.8. Italy
16.9. Netherlands
16.10. Nigeria
16.11. Norway
16.12. Poland
16.13. Qatar
16.14. Russia
16.15. Saudi Arabia
16.16. South Africa
16.17. Spain
16.18. Sweden
16.19. Switzerland
16.20. Turkey
16.21. United Arab Emirates
16.22. United Kingdom
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.2. AstraZeneca PLC
17.3.3. Bayer AG
17.3.4. Bristol Myers Squibb Company
17.3.5. Cipla Limited
17.3.6. Eli Lilly and Company
17.3.7. F. Hoffmann-La Roche AG
17.3.8. Johnson & Johnson Services, Inc.
17.3.9. Lupin Limited
17.3.10. Merck & Co., Inc.
17.3.11. Novartis AG
17.3.12. Otsuka Pharmaceutical Co., Ltd.
17.3.13. Pfizer, Inc.
17.3.14. Sanofi S.A.
17.3.15. Takeda Pharmaceutical Company
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. TUBERCULOSIS DRUGS MARKET MULTI-CURRENCY
FIGURE 2. TUBERCULOSIS DRUGS MARKET MULTI-LANGUAGE
FIGURE 3. TUBERCULOSIS DRUGS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. TUBERCULOSIS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. TUBERCULOSIS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TUBERCULOSIS DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CUSTOMIZED COMBINATION THERAPIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ETHAMBUTOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ISONIAZID, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY PYRAZINAMIDE, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RIFAMPICIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY BEDAQUILINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DELAMANID, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LEVOFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY MOXIFLOXACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY AMIKACIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY CAPREOMYCIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LONG-COURSE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SHORT-COURSE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY NATURAL AND HERBAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SYNTHETIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TUBERCULOSIS DRUGS MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 51. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 60. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 61. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 62. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 63. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 64. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 72. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 74. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 84. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 85. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 86. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 87. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 88. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 89. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 90. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 91. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 92. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 93. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 94. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. CANADA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 96. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 98. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 99. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 102. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 103. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 104. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 105. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 108. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 109. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 110. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 111. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 112. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TUBERCULOSIS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 121. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 122. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 123. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 124. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 125. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 135. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 136. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 137. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 138. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 146. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 147. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 148. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 149. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 150. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 151. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 152. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 153. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 154. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 155. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 156. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. CHINA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 158. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 159. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 160. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 161. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 162. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 163. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 164. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 165. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 166. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 167. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 168. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. INDIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 171. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 172. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 173. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 174. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 182. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 183. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 184. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 185. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 186. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 187. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 188. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 189. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 190. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 191. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 192. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. JAPAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 194. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 195. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 196. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 197. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 198. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 206. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 208. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 209. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 210. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 218. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 220. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 221. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 222. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 230. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 231. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 232. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 233. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 234. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 243. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 244. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 245. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 246. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 254. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 255. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 256. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 257. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 258. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 259. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 260. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 261. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 262. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 263. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 264. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. THAILAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 266. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 267. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 268. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 269. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 270. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 271. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 272. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 273. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 274. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 275. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 276. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 277. VIETNAM TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 291. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 292. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 293. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 294. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 296. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 297. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 298. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 299. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 300. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 301. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 302. DENMARK TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 303. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 304. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 305. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 306. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 307. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 308. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 309. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 310. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 311. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 312. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 313. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 314. EGYPT TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 315. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 316. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 317. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 318. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 319. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 320. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 321. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 322. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 323. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2030 (USD MILLION)
TABLE 324. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 325. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 326. FINLAND TUBERCULOSIS DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 327. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 328. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY COMBINATION DRUGS, 2018-2030 (USD MILLION)
TABLE 329. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FIRST-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 330. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY NOVEL THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 331. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY SECOND-LINE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 332. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY FLUOROQUINOLONES, 2018-2030 (USD MILLION)
TABLE 333. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY INJECTABLE ANTI-TB DRUGS, 2018-2030 (USD MILLION)
TABLE 334. FRANCE TUBERCULOSIS DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MI

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer, Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company

Methodology

Loading
LOADING...

Related Topics

Related Reports

Anti-Tuberculosis Therapeutics Market 2025-2033 - Product Image

Anti-Tuberculosis Therapeutics Market 2025-2033

  • Report
  • 146 Pages
  • Global
From
Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Multidrug-resistant Tuberculosis Therapeutics Market by Drug Class, Treatment Type, Therapeutic Approach, Drug Formulation, Treatment Regimen Duration, End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Anti-Tuberculosis Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Tuberculosis Therapeutics Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 178 Pages
  • Global
From
Tuberculosis Therapeutics - Global Strategic Business Report - Product Image

Tuberculosis Therapeutics - Global Strategic Business Report

  • Report
  • 283 Pages
  • Global
From

About the Tuberculosis Drug Market

The Tuberculosis Drug market is a subset of the larger Respiratory Drug market. It is composed of drugs used to treat tuberculosis, a bacterial infection that affects the lungs and other parts of the body. These drugs are typically antibiotics, such as isoniazid, rifampicin, and ethambutol, and are used in combination to treat the infection. The drugs are usually taken for a period of six to nine months, and are often used in combination with other treatments, such as surgery or chemotherapy. The Tuberculosis Drug market is highly competitive, with many companies offering different combinations of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Sanofi, Merck, and Novartis. Other companies, such as Cipla, Lupin, and Sun Pharmaceuticals, also offer a range of tuberculosis drugs. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.